Complementary and Alternative Medicine During HIV Infection
According to the Joint United Nations Program of HIV/AIDS (UNAIDS) and the World Health Organization (WHO) (Joint United Nations Program of HIV/AIDS, 2001), as of the end of 2001, there were about 40 million adults and children living with human immunod-eficiency virus (HIV) infection. This total does not include the 20 million people around the world who already died of AIDS. Of the 40 million currently alive, 37.2 are adults, 17.6 are women, and more than 2.7 are children. In 2001, there were 5 million new cases of HIV infection in the world, and 3 million AIDS related deaths. The large majority (almost three quarters) live in Sub-Saharan Africa where the prevalence rate of the infection among adults is 8.4%; more than 55% of infected individuals are women. The second major pocket of HIV infection is in South and Southeast Asia, with more than 6 million people infected. In North America where the epidemic was first described, there are 940,000 individuals who are HIV- , and in Western Europe, 540,000. Furthermore, South America, China, and East-ern Europe are characterized by a rapid increase in infection rates. These dramatic numbers clearly indicate that the fight against HIV/AIDS is an absolute health, social, economical and political priority in all parts of the world.
KeywordsHuman Immunodeficiency Virus Human Immunodeficiency Virus Type Alternative Medicine Pneumocystis Carinii Pneumonia Joint United Nations Program
Unable to display preview. Download preview PDF.
- 1.M. S. Gottlieb, R. Schroff, H. M. Schanker, J. D. Weisman, P. T. Fan, R. A. Wolf and A. Saxon, Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 305(24), 1425–31 (1981).PubMedCrossRefGoogle Scholar
- 6.C. Mussini, P. Pezzotti, A. Govoni, V. Borghi, A. Antinori, A. d’Arminio Monforte, A. De Luca, N. Mongiardo, M. C. Cerri, F. Chiodo, E. Concia, L. Bonazzi, M. Moroni, L. Ortona, R. Esposito, A. Cos-sarizza and B. De Rienzo, Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study. J Infect Dis 181(5), 1635–42 (2000).PubMedCrossRefGoogle Scholar
- 7.C. Mussini, P. Pezzotti, A. Antinori, V. Borghi, A. Monforte, A. Govoni, A. De Luca, A. Ammassari, N. Mongiardo, M. C. Cerri, A. Bedini, C. Beltrami, M. A. Ursitti, T. Bini, A. Cossarizza and R. Esposito, Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group. Clin Infect Dis 36(5), 645–51 (2003).PubMedCrossRefGoogle Scholar
- 8.R. P. van Heeswijk, A. Veldkamp, J. W. Mulder, P. L. Meenhorst, J. M. Lange, J. H. Beijnen and R. M. Hoetelmans, Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther 6(4), 201–29 (2001).PubMedGoogle Scholar
- 15.C. Rowlands and W. G. Powderly, The use of alternative therapies by HIV-positive patients attending the St. Louis AIDS Clinical Trials Unit. Mol Med 88(12), 807–10 (1991).Google Scholar